Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses - Université Paris-Est-Créteil-Val-de-Marne
Journal Articles Journal of Thoracic Oncology Year : 2020

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Tibor Csoszi
  • Function : Author
Gyula Ostoros
  • Function : Author
Zsuzsanna Mark
  • Function : Author
Christina Baik
  • Function : Author
Anil Abraham Joy
  • Function : Author
Jesus Corral Jaime
  • Function : Author
Vitezslav Kolek
  • Function : Author
Jaromir Roubec
  • Function : Author
Edgardo S Santos
  • Function : Author
Anne C Chiang
  • Function : Author
Giovanna Speranza
  • Function : Author
Chandra P Belani
  • Function : Author
Alberto Chiappori
  • Function : Author
Krisztina Czebe
  • Function : Author
Emily Sheldon-Waniga
  • Function : Author
Miguel Williams
  • Function : Author
Sunita Badola
  • Function : Author
Lisa Bedford
  • Function : Author
Jeffrey A Ecsedy
  • Function : Author
Matthew Bryant
  • Function : Author
Sian Jones
  • Function : Author
John Simmons
  • Function : Author
E. Jane Leonard
  • Function : Author
Claudio Dansky Ullmann
  • Function : Author
David R Spigel
  • Function : Author
Fichier principal
Vignette du fichier
PIIS1556086419335725.pdf (425.71 Ko) Télécharger le fichier
Origin Publication funded by an institution

Dates and versions

hal-04145712 , version 1 (29-06-2023)

Identifiers

Cite

Taofeek K Owonikoko, Huifeng Niu, Kristiaan Nackaerts, Tibor Csoszi, Gyula Ostoros, et al.. Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses. Journal of Thoracic Oncology, 2020, 15 (2), pp.274-287. ⟨10.1016/j.jtho.2019.10.013⟩. ⟨hal-04145712⟩

Collections

CNRS IMRB UPEC
4 View
21 Download

Altmetric

Share

More